NIKKEI 225
39,173.15 +368.50 (+0.95%) HANG SENG
18,058.96 +31.25 (+0.17%) CRUDE OIL
81.66 +0.03 (+0.04%) GOLD FUTURES
2,336.70 -7.70 (-0.33%) DOW
39,411.21 +260.91 (+0.67%) Bitcoin GBP
48,062.34 -1,016.06 (-2.07%)
REGN Jun 2024 890.000 put
| Previous close | 8.20 |
| Open | 8.20 |
| Bid | 0.00 |
| Ask | 4.80 |
| Strike | 890.00 |
| Expiry date | 2024-06-28 |
| Day's range | 8.20 - 8.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksRegeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
GlobeNewswireUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
Simply Wall St.Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past five years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
